WORCESTER, MA--(MARKET WIRE)--Jun 14, 2007 -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News) announced today that its wholly owned subsidiary, Antigen Express, Inc., has been awarded two new United States patents strengthening its core vaccine technology platform. The first patent, titled Ii-Key/Antigenic Epitope Hybrid Peptide Vaccine, and the second patent, titled Hybrid Peptides Modulate the Immune Response, both help secure the novel Antigen Express vaccine technology platform which is the foundation for a number of vaccine products presently in clinical development.
